Stirling J, Barkus E J, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, Lewis S
Department of Psychology and Speech Pathology, Manchester Metropolitan University, Manchester, UK.
Psychopathology. 2008;41(6):371-8. doi: 10.1159/000155215. Epub 2008 Sep 12.
Cannabis use has been identified as a possible risk factor for developing schizophrenia. In a previous paper we reported preliminary evidence that cannabis use increases the likelihood of psychosis-like experiences in non-clinical respondents who scored highly on a measure of schizotypy. We now present findings from pooled data from 3 new follow-up studies comprising a sample of 477 respondents, of whom 332 reported using cannabis at least once.
As in our previous study, the psychological effects of cannabis were assessed with the Cannabis Experiences Questionnaire, from which 3 subscales can be derived; encompassing pleasurable experiences, psychosis-like experiences and after-effects. The respondents also completed the brief Schizotypal Personality Questionnaire.
Cannabis use was reported by 70% of the sample. Use per se was not significantly related to schizotypy. However, high scoring schizotypes were more likely to report both psychosis-like experiences and unpleasant after-effects associated with cannabis use. The pleasurable effects of cannabis use were not related to schizotypy. Exploratory factor analysis of the pooled data from this study and our previous report (providing a sample of >400 cannabis users) suggested a 3-factor solution. These were characterised as a psychotic-dysphoric index (factor 1), an expansive index (factor 2) and an intoxicated index (factor 3). Schizotypy was highly correlated with factors 1 and 3, though not with factor 2.
High scoring schizotypes who use cannabis are more likely to experience psychotic-dysphoric phenomena and intoxicating effects during and after use. Our results confirm and expand the findings reported in our previous study. They are consistent with the hypothesis that cannabis use may be a risk factor for full psychosis in this group.
大麻使用已被确定为患精神分裂症的一个可能风险因素。在之前的一篇论文中,我们报告了初步证据,表明大麻使用会增加在精神分裂症型人格测量中得分较高的非临床受访者出现类精神病体验的可能性。我们现在展示来自3项新的随访研究汇总数据的结果,这些研究样本包括477名受访者,其中332人报告至少使用过一次大麻。
与我们之前的研究一样,使用《大麻体验问卷》评估大麻的心理影响,该问卷可得出3个分量表;包括愉悦体验、类精神病体验和后效应。受访者还完成了简短的《分裂型人格问卷》。
70%的样本报告使用过大麻。使用大麻本身与精神分裂症型人格并无显著关联。然而,得分高的精神分裂症型人格者更有可能报告与大麻使用相关的类精神病体验和不愉快的后效应。大麻使用的愉悦效果与精神分裂症型人格无关。对本研究和我们之前报告(提供了一个超过400名大麻使用者的样本)的汇总数据进行探索性因素分析,得出了一个三因素解决方案。这些因素被表征为一个精神病性烦躁指数(因素1)、一个欣快指数(因素2)和一个中毒指数(因素3)。精神分裂症型人格与因素1和3高度相关,但与因素2无关。
使用大麻的得分高的精神分裂症型人格者在使用期间及之后更有可能经历精神病性烦躁现象和中毒效应。我们的结果证实并扩展了我们之前研究中报告的发现。它们与大麻使用可能是该群体中出现完全精神病的一个风险因素这一假设一致。